on ADVICENNE (EPA:ADVIC)
Advicenne presents its 2025 annual financial results
The pharmaceutical company Advicenne unveiled its financial results for the 2025 financial year, showing a turnover of 5.8 million euros, an increase of 18.7% compared to 2024. European sales of Sibnayal®, their main product, saw impressive growth of more than 71%, reaching almost 11 million euros.
In terms of royalties, the company has doubled its revenue, receiving 1.1 million euros in 2025. However, the net loss amounts to 9.53 million euros, impacted by a significant tax burden in France.
Advicenne continues to invest in the development of Sibnayal® in the United States, where marketing authorization is expected for September 2026.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADVICENNE news